Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with ComirnatyⓇ: A randomized, observer-blind, controlled, phase 1 study

IF 4.8 2区 医学 Q1 INFECTIOUS DISEASES International Journal of Infectious Diseases Pub Date : 2024-09-11 DOI:10.1016/j.ijid.2024.107237
Samba O. Sow , Milagritos D. Tapia , Fadima C. Haidara , Fatoumata Diallo , Xi Han , Jingjing Chen , Lei Shi , Qing Yang , Bangwei Yu , Yalin Hu , Lin Yuan , Ge Liu , Silvia Grappi , Martina Monti , Simonetta Viviani , Min Ji , Chenliang Zhou
{"title":"Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with ComirnatyⓇ: A randomized, observer-blind, controlled, phase 1 study","authors":"Samba O. Sow ,&nbsp;Milagritos D. Tapia ,&nbsp;Fadima C. Haidara ,&nbsp;Fatoumata Diallo ,&nbsp;Xi Han ,&nbsp;Jingjing Chen ,&nbsp;Lei Shi ,&nbsp;Qing Yang ,&nbsp;Bangwei Yu ,&nbsp;Yalin Hu ,&nbsp;Lin Yuan ,&nbsp;Ge Liu ,&nbsp;Silvia Grappi ,&nbsp;Martina Monti ,&nbsp;Simonetta Viviani ,&nbsp;Min Ji ,&nbsp;Chenliang Zhou","doi":"10.1016/j.ijid.2024.107237","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>ZR-202-CoV and ZR-202a-CoV are novel recombinant vaccines containing 25 µg of the prototype (Wuhan strain) or B.1.351 strain (Beta variant) SARS-CoV-2 S-protein expressed in CHO cells, respectively, adjuvanted with Al(OH)<sub>3</sub> and CpG-ODN. We assessed their safety and immunogenicity in this Phase I, randomized, observer-blind, controlled study in Mali.</div></div><div><h3>Design</h3><div>Sixty healthy 18–55-year-old adults randomized 1:1:1 received two doses of ZR-202-CoV, ZR-202a-CoV, or Comirnaty<sup>Ⓡ</sup> 28 days apart. Primary outcome measures were solicited and unsolicited adverse events (AEs) including AESI (Adverse Events of Special Interest); secondary outcome was immunogenicity measured as SARS-CoV-2 specific neutralizing antibodies. Participants were followed up for 1 year.</div></div><div><h3>Results</h3><div>Injection site pain and headache were the most frequent solicited local and systemic AEs, respectively. No unsolicited AEs or SAEs related to vaccination were reported during the study period. Although most participants had detectable neutralizing antibodies at baseline robust immune responses were observed in all vaccine groups after the first dose with no further increase after the second dose. Cross-neutralizing antibody responses against Beta, Delta, and Omicron BA.5 variants were similar in magnitude after ZR-202-CoV, ZR-202a-CoV and Comirnaty<sup>Ⓡ</sup>.</div></div><div><h3>Conclusions</h3><div>Similar reactogenicity and immunogenicity profiles of ZR-202-CoV, ZR-202a-CoV and Comirnaty<sup>Ⓡ</sup> support further clinical investigation in a wider population.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"148 ","pages":"Article 107237"},"PeriodicalIF":4.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224003084","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

ZR-202-CoV and ZR-202a-CoV are novel recombinant vaccines containing 25 µg of the prototype (Wuhan strain) or B.1.351 strain (Beta variant) SARS-CoV-2 S-protein expressed in CHO cells, respectively, adjuvanted with Al(OH)3 and CpG-ODN. We assessed their safety and immunogenicity in this Phase I, randomized, observer-blind, controlled study in Mali.

Design

Sixty healthy 18–55-year-old adults randomized 1:1:1 received two doses of ZR-202-CoV, ZR-202a-CoV, or Comirnaty 28 days apart. Primary outcome measures were solicited and unsolicited adverse events (AEs) including AESI (Adverse Events of Special Interest); secondary outcome was immunogenicity measured as SARS-CoV-2 specific neutralizing antibodies. Participants were followed up for 1 year.

Results

Injection site pain and headache were the most frequent solicited local and systemic AEs, respectively. No unsolicited AEs or SAEs related to vaccination were reported during the study period. Although most participants had detectable neutralizing antibodies at baseline robust immune responses were observed in all vaccine groups after the first dose with no further increase after the second dose. Cross-neutralizing antibody responses against Beta, Delta, and Omicron BA.5 variants were similar in magnitude after ZR-202-CoV, ZR-202a-CoV and Comirnaty.

Conclusions

Similar reactogenicity and immunogenicity profiles of ZR-202-CoV, ZR-202a-CoV and Comirnaty support further clinical investigation in a wider population.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与 Comirnaty® 相比,ZR-202-CoV 和 ZR-202a-CoV 重组疫苗的安全性、反应原性和免疫原性:一项随机、观察者盲法对照的 1 期研究。
目的:ZR-202-CoV 和 ZR-202a-CoV 是新型重组疫苗,分别含有 25 µg 在 CHO 细胞中表达的原型(武汉株)或 B.1.351 株(Beta 变种)SARS-CoV-2 S 蛋白,并添加了 Al(OH)3 和 CpG-ODN 佐剂。我们在马里进行的这项一期随机、观察盲法对照研究中评估了它们的安全性和免疫原性:设计:60 名 18-55 岁的健康成年人按 1:1:1 的比例随机接受两剂 ZR-202-CoV、ZR-202a-CoV 或 Comirnaty® ,每剂相隔 28 天。主要结果指标为主动和非主动不良事件(AEs),包括AESI(特别关注不良事件);次要结果指标为免疫原性,即SARS-CoV-2特异性中和抗体。对参与者进行了为期一年的随访:结果:注射部位疼痛和头痛分别是最常见的局部和全身不良反应。在研究期间,没有报告与疫苗接种相关的主动性AE或SAE。虽然大多数参与者在基线时就能检测到中和抗体,但在接种第一剂疫苗后,所有疫苗组都观察到了强大的免疫反应,第二剂疫苗接种后免疫反应没有进一步增强。ZR-202-CoV、ZR-202a-CoV 和 Comirnaty® 对 Beta、Delta 和 Omicron BA.5 变体的交叉中和抗体反应程度相似:结论:ZR-202-CoV、ZR-202a-CoV 和 Comirnaty® 具有相似的反应原性和免疫原性特征,支持在更广泛的人群中开展进一步的临床研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
18.90
自引率
2.40%
发文量
1020
审稿时长
30 days
期刊介绍: International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.
期刊最新文献
Microbiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru. Is intestinal colonization with multidrug-resistant Enterobacterales associated with higher rates of nosocomial Enterobacterales bloodstream infections? Relative efficacy of anti-Plasmodium vivax malaria combination drugs in preventing transmission to two major Anopheles mosquitoes in the first few days of treatment. Evaluating a rapid molecular assay in a mobile laboratory for improved diagnosis of dengue in Bangladesh. Post-acute sequelae of COVID-19 3 to 12 months after infection: Delta vs Omicron.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1